🎉 M&A multiples are live!
Check it out!

Prelude Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Prelude Therapeutics and similar public comparables like Pharming, Vivoryon Therapeutics, and Benevolent AI.

Prelude Therapeutics Overview

About Prelude Therapeutics

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.


Founded

2016

HQ

United States of America
Employees

131

Website

preludetx.com

Financials

LTM Revenue $5.0M

LTM EBITDA n/a

EV

-$77.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Prelude Therapeutics Financials

Prelude Therapeutics has a last 12-month revenue of $5.0M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Prelude Therapeutics achieved revenue of $7.0M and an EBITDA of -$138M.

Prelude Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Prelude Therapeutics valuation multiples based on analyst estimates

Prelude Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $7.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$131M -$138M XXX XXX XXX
EBITDA Margin -Infinity% -1971% XXX XXX XXX
Net Profit -$115M -$122M XXX XXX XXX
Net Margin -Infinity% -1740% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Prelude Therapeutics Stock Performance

As of April 15, 2025, Prelude Therapeutics's stock price is $1.

Prelude Therapeutics has current market cap of $38.3M, and EV of -$77.3M.

See Prelude Therapeutics trading valuation data

Prelude Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$77.3M $38.3M XXX XXX XXX XXX $-1.66

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Prelude Therapeutics Valuation Multiples

As of April 15, 2025, Prelude Therapeutics has market cap of $38.3M and EV of -$77.3M.

Prelude Therapeutics's trades at -15.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Prelude Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Prelude Therapeutics and 10K+ public comps

Prelude Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$77.3M XXX XXX XXX
EV/Revenue -11.0x XXX XXX XXX
EV/EBITDA 0.6x XXX XXX XXX
P/E -0.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Prelude Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Prelude Therapeutics Valuation Multiples

Prelude Therapeutics's NTM/LTM revenue growth is -100%

Prelude Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Prelude Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Prelude Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Prelude Therapeutics and other 10K+ public comps

Prelude Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -1971% XXX XXX XXX XXX
EBITDA Growth 5% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 410% XXX XXX XXX XXX
R&D Expenses to Revenue 1686% XXX XXX XXX XXX
Opex to Revenue 2096% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Prelude Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Prelude Therapeutics M&A and Investment Activity

Prelude Therapeutics acquired  XXX companies to date.

Last acquisition by Prelude Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Prelude Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Prelude Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Prelude Therapeutics

When was Prelude Therapeutics founded? Prelude Therapeutics was founded in 2016.
Where is Prelude Therapeutics headquartered? Prelude Therapeutics is headquartered in United States of America.
How many employees does Prelude Therapeutics have? As of today, Prelude Therapeutics has 131 employees.
Who is the CEO of Prelude Therapeutics? Prelude Therapeutics's CEO is Dr. Krishna Vaddi, PhD.
Is Prelude Therapeutics publicy listed? Yes, Prelude Therapeutics is a public company listed on NAS.
What is the stock symbol of Prelude Therapeutics? Prelude Therapeutics trades under PRLD ticker.
When did Prelude Therapeutics go public? Prelude Therapeutics went public in 2020.
Who are competitors of Prelude Therapeutics? Similar companies to Prelude Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Prelude Therapeutics? Prelude Therapeutics's current market cap is $38.3M
What is the current revenue of Prelude Therapeutics? Prelude Therapeutics's last 12-month revenue is $5.0M.
What is the current EV/Revenue multiple of Prelude Therapeutics? Current revenue multiple of Prelude Therapeutics is -15.5x.
Is Prelude Therapeutics profitable? Yes, Prelude Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.